{'fraction_non_alphanumeric': 0.033646322378716745, 'fraction_numerical': 0.011737089201877934, 'mean_word_length': 5.731578947368421, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Isoprenoids modulate expression of Fe65 in cultured cells

Fe65 binds to the amyloid precursor protein (APP), a central protein in Alzheimer's disease pathology with unknown physiological function. Fe65 has been shown to have a role in the regulation of APP processing. It interacts with the APP intracellular domain and the LDL‐receptor‐related protein, which increases transcriptional events and intracellular signaling, respectively. Using SH‐SY5Y neuroblastoma cells, the cholesterol and isoprenoid pathways were manipulated to determine the changes in Fe65 expression. We used complete (FBS) and lipoprotein‐deficient serum (LDFBS) with simvastatin (SV), mevalonate or methyl‐beta‐cyclodextrin (MBCD), to assess distinct effects of isoprenoids and cholesterol (see Table ). Fe65 was increased in a normal cholesterol (FBS) and normal isoprenoid (mevalonate rescued) environment in an SV dose‐dependent manner. Interestingly, the cells in low cholesterol (LDFBS) had an inverse response to SV. This decrease was enhanced by the addition of mevalonate. This suggests that isoprenoids may regulate Fe65 in cell culture. Ongoing experiments will further dissect the role of the isoprenoids and cholesterol in the regulation of APP metabolism by Fe65 and other adaptor proteins.